banner
Health Team

Eli Lilly pauses trial of its monoclonal antibody to treat coronavirus because of illness

Posted October 13, 2020 3:16 p.m. EDT

— Drugmaker Eli Lilly said Tuesday it is pausing its trial of a combination antibody treatment for coronavirus for safety reasons.

Usually, clinical trials are paused because a volunteer has suffered a side effect or become ill, but the company did not say what happened.

"Safety is of the (utmost) importance to Lilly," a spokesperson told CNN by email.

It said the trial's Data Safety Monitoring Board (DSMB), an independent group of medical experts who monitor clinical trials, recommended the pause.

"The trial, evaluating Lilly's investigational neutralizing antibody as a treatment for COVID-19 in hospitalized patients, is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). Lilly is supportive of the decision by the independent DSMB to cautiously ensure the safety of the patients participating in this study," the company said in the statement.

Lilly is testing a combination of two lab-engineered immune system proteins called monoclonal antibodies to treat severely ill patients with coronavirus. It is similar to the treatment made by Regeneron that was given to President Trump earlier this month.

Our commenting policy has changed. If you would like to comment, please share on social media using the icons below and comment there.